We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+55.06%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.8B
AUM Growth
+$694M
(+33%)
Cap. Flow
+$99M
Cap. Flow
% of AUM
3.54%
Top 10 Holdings %
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5
Top Buys
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$63.5M |
| 2 |
Immunome
IMNM
|
+$32.3M |
| 3 |
Biohaven
BHVN
|
+$28.8M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$27.9M |
| 5 |
Abbott
ABT
|
+$26.5M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
+$30M |
| 2 |
Humana
HUM
|
+$29.1M |
| 3 |
Elevance Health
ELV
|
+$28.8M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$24M |
| 5 |
DexCom
DXCM
|
+$22.8M |
Sector Composition
| 1 | Healthcare | 94.12% |
| 2 | Industrials | 3.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
IDEAYA Biosciences
IDYA
$3.55B
| $33.3M | 1.19% |
+935,863
| New | +$27.9M |
|
27
Replimune Group
REPL
$827M
| $32.6M | 1.17% |
3,865,258
-298,664
| -7% | -$3.46M |
|
28
Cabaletta Bio
CABA
$452M
| $31.2M | 1.12% |
1,374,189
-400,063
| -23% | -$6.73M |
|
|
29
Abbott
ABT
$155B
| $29.2M | 1.05% |
+265,500
| New | +$26.5M |
|
30
Evolent Health
EVH
$651M
| $27.6M | 0.99% |
835,537
+370,255
| +80% | +$10.5M |
|
|
AKRO
31
DELISTED
Akero Therapeutics
AKRO
| $25.9M | 0.93% |
1,109,476
-660,208
| -37% | -$13M |
|
32
ADC Therapeutics
ADCT
$162M
| $25.4M | 0.91% |
15,328,317
+1,150,272
| +8% | +$1.06M |
|
33
Annexon
ANNX
$990M
| $25M | 0.89% |
5,503,190
+2,000,000
| +57% | +$4.95M |
|
|
IGMS
34
DELISTED
IGM Biosciences
IGMS
| $24.7M | 0.88% |
2,971,542
| – | – |
|
|
VERV
35
DELISTED
Verve Therapeutics
VERV
| $24M | 0.86% |
1,718,669
+908,892
| +112% | +$11.3M |
|
36
Penumbra
PEN
$12.5B
| $24M | 0.86% |
95,242
-59,834
| -39% | -$13.2M |
|
|
ETNB
37
DELISTED
89bio
ETNB
| $22M | 0.79% |
1,969,402
+1,207,447
| +158% | +$11.1M |
|
38
Charles River Laboratories
CRL
$11.1B
| $20.5M | 0.73% |
86,782
+20,400
| +31% | +$4.01M |
|
39
Entrada Therapeutics
TRDA
$270M
| $19.4M | 0.69% |
1,283,735
-265
| -0% | -$3.93K |
|
40
Neurogene
NGNE
$787M
| $18.4M | 0.66% |
946,897
+801,286
| +550% | +$11.5M |
|
41
Intuitive Surgical
ISRG
$139B
| $18.3M | 0.65% |
+54,258
| New | +$16.2M |
|
42
HCA Healthcare
HCA
$83.6B
| $17.9M | 0.64% |
66,100
+41,433
| +168% | +$10.2M |
|
43
Cogent Biosciences
COGT
$6.76B
| $17.1M | 0.61% |
2,914,022
+860,689
| +42% | +$6.6M |
|
44
Stryker
SYK
$121B
| $15.9M | 0.57% |
53,141
-41,597
| -44% | -$11.7M |
|
|
RPTX
45
DELISTED
Repare Therapeutics
RPTX
| $15.7M | 0.56% |
2,148,748
-255,947
| -11% | -$1.43M |
|
46
Stoke Therapeutics
STOK
$1.86B
| $13.8M | 0.49% |
2,625,506
-1,247,190
| -32% | -$5.33M |
|
47
Align Technology
ALGN
$12.9B
| $13.7M | 0.49% |
+50,082
| New | +$11.9M |
|
|
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $12M | 0.43% |
5,872,605
-2,636,521
| -31% | -$4.81M |
|
49
Prime Medicine
PRME
$627M
| $11.7M | 0.42% |
1,324,350
| – | – |
|
|
50
Elevance Health
ELV
$85.1B
| $10.9M | 0.39% |
23,079
-62,299
| -73% | -$28.8M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO